Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. However, onc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Pharmacol
Autori principali: Vella Bonanno, Patricia, Ermisch, Michael, Godman, Brian, Martin, Antony P., Van Den Bergh, Jesper, Bezmelnitsyna, Liudmila, Bucsics, Anna, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz, van de Casteele, Marc, Diogene, Eduardo, Eriksson, Irene, Fürst, Jurij, Gad, Mohamed, Greičiūtė-Kuprijanov, Ieva, van der Graaff, Martin, Gulbinovic, Jolanta, Jones, Jan, Joppi, Roberta, Kalaba, Marija, Laius, Ott, Langner, Irene, Mardare, Ileana, Markovic-Pekovic, Vanda, Magnusson, Einar, Melien, Oyvind, Meshkov, Dmitry O., Petrova, Guenka I., Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Schuurman, Ad, Ramos, Ricardo, Rodrigues, Jorge, Zara, Corinne, Zebedin-Brandl, Eva, Haycox, Alan
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2017
Soggetti:
Pharmacology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5572364/
https://ncbi.nlm.nih.gov/pubmed/28878667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00497
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi